Integrable circuit principle for synthesizing voltage-controlled nonlinear impedances

S. Pookaiyaudom,C. Surawatpanya

DOI: https://doi.org/10.1109/PROC.1978.11120

IF: 20.6

1978-10-01

Proceedings of the IEEE

Abstract:An integrable circuit principle is described, whereby a large class of arbitrary voltage-controlled nonlinear impedances can be accurately synthesized.

What problem does this paper attempt to address?

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Jerica Wilson,Bahrad A. Sokhansanj,Wei Chuen Chong,Rohan Chandraghatgi,Gail L. Rosen,Hai-Feng Ji

DOI: https://doi.org/10.1016/j.jmgm.2023.108669

2024-01-01

Abstract:Fragment-based drug design (FBDD) is one major drug discovery method employed in computer-aided drug discovery. Due to its inherent limitations, this process experiences long processing times and limited success rates. Here we present a new Fragment Databases from Screened Ligands Drug Design method (FDSL-DD) that intelligently incorporates information about fragment characteristics into a fragment-based design approach to the drug development process. The initial step of the FDSL-DD is the creation of a fragment database from a library of docked, drug-like ligands for a specific target, which deviates from the traditional in silico FBDD strategy, incorporating structure-based design screening techniques to combine the advantages of both approaches. Three different protein targets have been tested in this study to demonstrate the potential of the created fragment library and FDSL-DD. Utilizing the FDSL-DD led to an increase in binding affinity for each protein target. The most substantial increase was exhibited by the ligand designed for TIPE2, with a 3.6 kcalmol-1 difference between the top ligand from the FDSL-DD and top ligand from the high throughput virtual screening (HTVS). Using drug-like ligands in the initial HTVS allows for a greater search of chemical space, with higher efficiency in fragments selection, less grid boxes, and potentially identifying more interactions.
Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Rohan Chandraghatgi,Hai-Feng Ji,Gail L. Rosen,Bahrad A. Sokhansanj

DOI: https://doi.org/10.1021/acs.jcim.4c00234

IF: 6.162

2024-01-01

Journal of Chemical Information and Modeling

Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.
Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Tao Wang,Mian-Bin Wu,Zheng-Jie Chen,Hua Chen,Jian-Ping Lin,Li-Rong Yang

DOI: https://doi.org/10.2174/1389201015666141122204532

2015-01-01

Current Pharmaceutical Biotechnology

Abstract:Fragment-based drug discovery (FBDD) has caused a revolution in the process of drug discovery and design, with many FBDD leads being developed into clinical trials or approved in the past few years. Compared with traditional high-throughput screening, it displays obvious advantages such as efficiently covering chemical space, achieving higher hit rates, and so forth. In this review, we focus on the most recent developments of FBDD for improving drug discovery, illustrating the process and the importance of FBDD. In particular, the computational strategies applied in the process of FBDD and molecular-docking programs are highlighted elaborately. In most cases, docking is used for predicting the ligand-receptor interaction modes and hit identification by structurebased virtual screening. The successful cases of typical significance and the hits identified most recently are discussed.
Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology

Matteo P. Ferla,Rubén Sánchez-García,Rachael E. Skyner,Stefan Gahbauer,Jenny C. Taylor,Frank von Delft,Brian D. Marsden,Charlotte M. Deane

DOI: https://doi.org/10.26434/chemrxiv-2024-17w01

2024-02-26

Abstract:Current strategies centred on either merging or linking initial hits from fragment-based drug design (FBDD) crystallographic screens ignore 3D structural information. We show that an algorithmic approach (Fragmenstein) that ‘stitches’ the ligand atoms from this structural information together can provide more accurate and reliable predictions for protein-ligand complex conformation than existing methods such as pharmacophore-constrained docking. This approach works under the assumption of conserved binding: when a larger molecule is designed containing the initial fragment hit, the common substructure between the two will adopt the same binding mode. Fragmenstein either takes the coordinates of ligands from a experimental fragment screen and stitches the atoms together to produce a novel merged compound, or uses them to predict the complex for a provided compound. The compound is then energy minimised under strong constraints to obtain a structurally plausible compound. This method is successful in showing the importance of using the coordinates of known binders when predicting the conformation of derivative compounds through a retrospective analysis of the COVID Moonshot data. It has also had a real-world application in hit-to-lead screening, yielding a sub-micromolar merger from parent hits in a single round.

Chemistry
MolHyb: A Web Server for Structure-Based Drug Design by Molecular Hybridization

Hao Wang,Xiaolin Pan,Yueqing Zhang,Xingyu Wang,Xudong Xiao,Changge Ji

DOI: https://doi.org/10.1021/acs.jcim.2c00443

IF: 6.162

2022-06-13

Journal of Chemical Information and Modeling

Abstract:Molecular hybridization is a widely used ligand design method in drug discovery. In this study, we present MolHyb, a web server for structure-based ligand design by molecular hybridization. The input of MolHyb is a protein file and a seed compound file. MolHyb tries to generate novel ligands through hybridizing the seed compound with helper compounds that bind to the same protein target or similar proteins. To facilitate the job of getting helper compounds, we compiled a modeled protein-ligand structure database as an extension to crystal structures in the PDB database by placing the bioactive compounds in ChEMBL into their corresponding 3D protein binding pocket properly. MolHyb works by searching for helper compounds from the protein-ligand structure database and migrating chemical moieties from helper compounds to the seed compound efficiently. Hybridization is performed at both cyclic and acyclic bonds. The users can also input their own helper compounds to MolHyb. We hope that MolHyb will be a useful tool for rational drug design. MolHyb is freely available at http://molhyb.xundrug.cn/.

chemistry, multidisciplinary, medicinal,computer science, interdisciplinary applications, information systems
FragGen: Towards 3D Geometry Reliable Fragment-based Molecular Generation

Mengyao Yu,Yundian Zeng,Mingyang Wang,Chenqing Hua,Sunliang Cui,Peichen Pan,Chang-Yu Hsieh,Tingjun Hou,Odin Zhang,Yufei Huang,Shicheng Chen,Xujun Zhang,Haitao Lin,Zhenxing Wu,Huifeng Zhao,Zaixi Zhang,Yu Kang

DOI: https://doi.org/10.1039/d4sc04620j

IF: 8.4

2024-10-18

Chemical Science

Abstract:3D structure-based molecular generation is a successful application of generative AI in drug discovery. Most earlier models follow an atom-wise paradigm, generating molecules with good docking scores but poor molecular properties (like synthesizability and drugability). In contrast, fragment-wise generation offers a promising alternative by assembling chemically viable fragments. However, the co-design of plausible chemical and geometrical structures is still challenging, as evidenced by existing models. To address this, we introduce the Deep Geometry Handling protocol, which decomposes the entire geometry into multiple sets of geometric variables, looking beyond model architecture design. Drawing from a newly defined six-category taxonomy, we propose FragGen, a novel hybrid strategy as the first geometry-reliable, fragment-wise molecular generation method. FragGen significantly enhances both the geometric quality and synthesizability of the generated molecules, overcoming major limitations of previous models. Moreover, FragGen has been successfully applied in real-world scenarios, notably in designing type II kinase inhibitors at the ~nM level, establishing it as the first validated 3D fragment-based drug design algorithm. We believe that this concept-algorithm-application cycle will not only inspire researchers working on other geometry-centric tasks to move beyond architecture designs but also provide a solid example of how generative AI can be customized for drug design.

chemistry, multidisciplinary
FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening

Hongyi Zhou,Hongnan Cao,Jeffrey Skolnick

DOI: https://doi.org/10.1021/acs.jcim.0c01160

IF: 6.162

2021-03-16

Journal of Chemical Information and Modeling

Abstract:To reduce time and cost, virtual ligand screening (VLS) often precedes experimental ligand screening in modern drug discovery. Traditionally, high-resolution structure-based docking approaches rely on experimental structures, while ligand-based approaches need known binders to the target protein and only explore their nearby chemical space. In contrast, our structure-based FINDSITEcomb2.0 approach takes advantage of predicted, low-resolution structures and information from ligands that bind distantly related proteins whose binding sites are similar to the target protein. Using a boosted tree regression machine learning framework, we significantly improved FINDSITEcomb2.0 by integrating ligand fragment scores as encoded by molecular fingerprints with the global ligand similarity scores of FINDSITEcomb2.0. The new approach, FRAGSITE, exploits our observation that ligand fragments, e.g., rings, tend to interact with stereochemically conserved protein subpockets that also occur in evolutionarily unrelated proteins. FRAGSITE was benchmarked on the 102 protein DUD-E set, where any template protein whose sequence identify >30% to the target was excluded. Within the top 100 ranked molecules, FRAGSITE improves VLS precision and recall by 14.3 and 18.5%, respectively, relative to FINDSITEcomb2.0. Moreover, the mean top 1% enrichment factor increases from 25.2 to 30.2. On average, both outperform state-of-the-art deep learning-based methods such as AtomNet. On the more challenging unbiased set LIT-PCBA, FRAGSITE also shows better performance than ligand similarity-based and docking approaches such as two-dimensional ECFP4 and Surflex-Dock v.3066. On a subset of 23 targets from DEKOIS 2.0, FRAGSITE shows much better performance than the boosted tree regression-based, vScreenML scoring function. Experimental testing of FRAGSITE's predictions shows that it has more hits and covers a more diverse region of chemical space than FINDSITEcomb2.0. For the two proteins that were experimentally tested, DHFR, a well-studied protein that catalyzes the conversion of dihydrofolate to tetrahydrofolate, and the kinase ACVR1, FRAGSITE identified new small-molecule nanomolar binders. Interestingly, one new binder of DHFR is a kinase inhibitor predicted to bind in a new subpocket. For ACVR1, FRAGSITE identified new molecules that have diverse scaffolds and estimated nanomolar to micromolar affinities. Thus, FRAGSITE shows significant improvement over prior state-of-the-art ligand virtual screening approaches. A web server is freely available for academic users at <a class="extLink" href="http://http:/sites.gatech.edu/cssb/FRAGSITE">http:/sites.gatech.edu/cssb/FRAGSITE</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01160?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01160</a>.Additional information for experimental methods and (Tables S1 and S2) top 40 most frequent fragments in DrugBank drugs and performance of methods for individual DUD-E targets using the modeled target structure (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01160/suppl_file/ci0c01160_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

chemistry, multidisciplinary, medicinal,computer science, interdisciplinary applications, information systems
LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design

Renxiao Wang,Ying Gao,Luhua Lai

DOI: https://doi.org/10.1007/s0089400060498

IF: 2.172

2000-01-01

Journal of Molecular Modeling

Abstract:We have developed a new multi-purpose program, LigBuilder, for structure-based drug design. Within the structural constraints of the target protein, LigBuilder builds up ligands step by step using a library of organic fragments. Various operations, such as growing, linking, and mutation, have been implemented to manipulate molecular structures. The user can choose either growing or linking strategies for ligand construction and a genetic algorithm is adopted to control the whole construction process. Binding affinities of the ligands are estimated by an empirical scoring function and the bioavailabilities are evaluated by a set of chemical rules. Using thrombin and dihydrofolate reductase as examples, we have demonstrated that LigBuilder is able to generate chemical structures similar to the known ligands.
Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

Alexander S. Powers,Helen H. Yu,Patricia Suriana,Ron O. Dror

DOI: https://doi.org/10.1101/2022.03.17.484653

2022-03-19

Abstract:A bstract Computationally-aided design of novel molecules has the potential to accelerate drug discovery. Several recent generative models aimed to create new molecules for specific protein targets. However, a rate limiting step in drug development is molecule optimization, which can take several years due to the challenge of optimizing multiple molecular properties at once. We developed a method to solve a specific molecular optimization problem in silico : expanding a small, fragment-like starting molecule bound to a protein pocket into a larger molecule that matches that physiochemical properties of known drugs. Using data-efficient E(3) equivariant based neural networks and a 3D atomic point cloud representation, our model learns how to attach new molecular fragments to a growing structure by recognizing realistic intermediates generated en route to a final ligand. This approach always generates chemically valid molecules and incorporates all relevant 3D spatial information from the protein pocket. This framework produces promising molecules as assessed by multiple properties that address binding affinity, ease of synthesis, and solubility. Overall, we demonstrate the feasibility of 3D molecular structure expansion conditioned on protein pockets while maintaining desirable drug-like physiochemical properties and developed a tool that could accelerate the work of medicinal chemists.
ChemGenerator: a web server for generating potential ligands for specific targets

Jing Yang,Ling Hou,Kun-Meng Liu,Wen-Bin He,Yong Cai,Feng-Qing Yang,Yuan-Jia Hu

DOI: https://doi.org/10.1093/bib/bbaa407

IF: 9.5

2020-12-31

Briefings in Bioinformatics

Abstract:Abstract In drug discovery, one of the most important tasks is to find novel and biologically active molecules. Given that only a tip of iceberg of drugs was founded in nearly one-century’s experimental exploration, it shows great significance to use in silico methods to expand chemical database and profile drug-target linkages. In this study, a web server named ChemGenerator was proposed to generate novel activates for specific targets based on users’ input. The ChemGenerator relies on an autoencoder-based algorithm of Recurrent Neural Networks with Long Short-Term Memory by training of 7 million of molecular Simplified Molecular-Input Line-Entry System as the basic model, and further develops target guided generation by transfer learning. As results, ChemGenerator gains lower loss (<0.01) than existing reference model (0.2~0.4) and shows good performance in the case of Epidermal Growth Factor Receptor. Meanwhile, ChemGenerator is now freely accessible to the public by http://smiles.tcmobile.org. In proportion to endless molecular enumeration and time-consuming expensive experiments, this work demonstrates an efficient alternative way for the first virtual screening in drug discovery.

biochemical research methods,mathematical & computational biology
FRAGSITE2: A structure and fragment-based approach for virtual ligand screening

Hongyi Zhou,Jeffrey Skolnick

DOI: https://doi.org/10.1002/pro.4869

Abstract:Protein function annotation and drug discovery often involve finding small molecule binders. In the early stages of drug discovery, virtual ligand screening (VLS) is frequently applied to identify possible hits before experimental testing. While our recent ligand homology modeling (LHM)-machine learning VLS method FRAGSITE outperformed approaches that combined traditional docking to generate protein-ligand poses and deep learning scoring functions to rank ligands, a more robust approach that could identify a more diverse set of binding ligands is needed. Here, we describe FRAGSITE2 that shows significant improvement on protein targets lacking known small molecule binders and no confident LHM identified template ligands when benchmarked on two commonly used VLS datasets: For both the DUD-E set and DEKOIS2.0 set and ligands having a Tanimoto coefficient (TC) < 0.7 to the template ligands, the 1% enrichment factor (EF1% ) of FRAGSITE2 is significantly better than those for FINDSITEcomb2.0 , an earlier LHM algorithm. For the DUD-E set, FRAGSITE2 also shows better ROC enrichment factor and AUPR (area under the precision-recall curve) than the deep learning DenseFS scoring function. Comparison with the RF-score-VS on the 76 target subset of DEKOIS2.0 and a TC < 0.99 to training DUD-E ligands, FRAGSITE2 has double the EF1% . Its boosted tree regression method provides for more robust performance than a deep learning multiple layer perceptron method. When compared with the pretrained language model for protein target features, FRAGSITE2 also shows much better performance. Thus, FRAGSITE2 is a promising approach that can discover novel hits for protein targets. FRAGSITE2's web service is freely available to academic users at http://sites.gatech.edu/cssb/FRAGSITE2.
In silico construction of a focused fragment library facilitating exploration of chemical space**

Weijie Han,Xiaohe Xu,Qing Fan,Yingchao Yan,YanMin Zhang,Yadong Chen,Haichun Liu

DOI: https://doi.org/10.1002/minf.202300256

IF: 4.05

2024-01-23

Molecular Informatics

Abstract:Abstract Fragment‐based drug design (FBDD) has emerged as a captivating subject in the realm of computer‐aided drug design, enabling the generation of novel molecules through the rearrangement of ring systems within known compounds. The construction of focused fragment library plays a pivotal role in FBDD, necessitating the compilation of all potential bioactive ring systems capable of interacting with a specific target. In our study, we propose a workflow for the development of a focused fragment library and combinatorial compound library. The fragment library comprises seed fragments and collected fragments. The extraction of seed fragments is guided by receptor information, serving as a prerequisite for establishing a focused libraries. Conversely, collected fragments are obtained using the feature graph method, which offers a simplified representation of fragments and strikes a balance between diversity and similarity when categorizing different fragments. The utilization of feature graph facilitates the rational partitioning of chemical space at fragment level, enabling the exploration of desired chemical space and enhancing the efficiency of screening compound library. Analysis demonstrates that our workflow enables the enumeration of a greater number of entirely new potential compounds, thereby aiding in the rational design of drugs.

chemistry, medicinal,mathematical & computational biology,computer science, interdisciplinary applications
DigFrag as a digital fragmentation method used for artificial intelligence-based drug design

Ruoqi Yang,Hao Zhou,Fan Wang,Guangfu Yang

DOI: https://doi.org/10.1038/s42004-024-01346-5

IF: 7.211

2024-11-13

Communications Chemistry

Abstract:Fragment-Based Drug Design (FBDD) plays a pivotal role in the field of drug discovery and development. The construction of high-quality fragment libraries is a critical step in FBDD. Conventional fragmentation approaches often rely on rigid rules and chemical intuition, limiting their adaptability to diverse molecular structures. The rapid development of Artificial Intelligence (AI) technology offers a transformative opportunity to rethink traditional methods. Here, we present DigFrag, a digital fragmentation method that highlights important substructures by focusing locally within the molecular graph. In addition, we feed the fragments segmented by machine intelligence and human expertise into the deep generative model to compare the preference for data from different sources. Experimental results show that the structural diversity of fragments segmented by DigFrag is higher, and more desirable compounds are generated based on these fragments. These results also demonstrate that data generated based on AI methods may be more suitable for AI models. Moreover, a user-friendly platform called MolFrag (https://dpai.ccnu.edu.cn/MolFrag/) is developed based on various fragmentation techniques to support molecular segmentation.

chemistry, multidisciplinary
Deep Geometry Handling and Fragment-wise Molecular 3D Graph Generation

Odin Zhang,Yufei Huang,Shichen Cheng,Mengyao Yu,Xujun Zhang,Haitao Lin,Yundian Zeng,Mingyang Wang,Zhenxing Wu,Huifeng Zhao,Zaixi Zhang,Chenqing Hua,Yu Kang,Sunliang Cui,Peichen Pan,Chang-Yu Hsieh,Tingjun Hou

2024-03-15

Abstract:Most earlier 3D structure-based molecular generation approaches follow an atom-wise paradigm, incrementally adding atoms to a partially built molecular fragment within protein pockets. These methods, while effective in designing tightly bound ligands, often overlook other essential properties such as synthesizability. The fragment-wise generation paradigm offers a promising solution. However, a common challenge across both atom-wise and fragment-wise methods lies in their limited ability to co-design plausible chemical and geometrical structures, resulting in distorted conformations. In response to this challenge, we introduce the Deep Geometry Handling protocol, a more abstract design that extends the design focus beyond the model architecture. Through a comprehensive review of existing geometry-related models and their protocols, we propose a novel hybrid strategy, culminating in the development of FragGen - a geometry-reliable, fragment-wise molecular generation method. FragGen marks a significant leap forward in the quality of generated geometry and the synthesis accessibility of molecules. The efficacy of FragGen is further validated by its successful application in designing type II kinase inhibitors at the nanomolar level.

Chemical Physics,Artificial Intelligence,Biomolecules
SpaceGrow: efficient shape-based virtual screening of billion-sized combinatorial fragment spaces

Sophia M. N. Hönig,Florian Flachsenberg,Christiane Ehrt,Alexander Neumann,Robert Schmidt,Christian Lemmen,Matthias Rarey

DOI: https://doi.org/10.1007/s10822-024-00551-7

IF: 4.179

2024-03-18

Journal of Computer-Aided Molecular Design

Abstract:The growing size of make-on-demand chemical libraries is posing new challenges to cheminformatics. These ultra-large chemical libraries became too large for exhaustive enumeration. Using a combinatorial approach instead, the resource requirement scales approximately with the number of synthons instead of the number of molecules. This gives access to billions or trillions of compounds as so-called chemical spaces with moderate hardware and in a reasonable time frame. While extremely performant ligand-based 2D methods exist in this context, 3D methods still largely rely on exhaustive enumeration and therefore fail to apply. Here, we present SpaceGrow: a novel shape-based 3D approach for ligand-based virtual screening of billions of compounds within hours on a single CPU. Compared to a conventional superposition tool, SpaceGrow shows comparable pose reproduction capacity based on RMSD and superior ranking performance while being orders of magnitude faster. Result assessment of two differently sized subsets of the eXplore space reveals a higher probability of finding superior results in larger spaces highlighting the potential of searching in ultra-large spaces. Furthermore, the application of SpaceGrow in a drug discovery workflow was investigated in four examples involving G protein-coupled receptors (GPCRs) with the aim to identify compounds with similar binding capabilities and molecular novelty.

biochemistry & molecular biology,biophysics,computer science, interdisciplinary applications
Autoregressive fragment-based diffusion for pocket-aware ligand design

Mahdi Ghorbani,Leo Gendelev,Paul Beroza,Michael J. Keiser

2023-12-15

Abstract:In this work, we introduce AutoFragDiff, a fragment-based autoregressive diffusion model for generating 3D molecular structures conditioned on target protein structures. We employ geometric vector perceptrons to predict atom types and spatial coordinates of new molecular fragments conditioned on molecular scaffolds and protein pockets. Our approach improves the local geometry of the resulting 3D molecules while maintaining high predicted binding affinity to protein targets. The model can also perform scaffold extension from user-provided starting molecular scaffold.

Biomolecules,Artificial Intelligence,Machine Learning,Chemical Physics,Quantitative Methods
DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design

Jiaqi Guan,Xiangxin Zhou,Yuwei Yang,Yu Bao,Jian Peng,Jianzhu Ma,Qiang Liu,Liang Wang,Quanquan Gu

2024-02-26

Abstract:Designing 3D ligands within a target binding site is a fundamental task in drug discovery. Existing structured-based drug design methods treat all ligand atoms equally, which ignores different roles of atoms in the ligand for drug design and can be less efficient for exploring the large drug-like molecule space. In this paper, inspired by the convention in pharmaceutical practice, we decompose the ligand molecule into two parts, namely arms and scaffold, and propose a new diffusion model, DecompDiff, with decomposed priors over arms and scaffold. In order to facilitate the decomposed generation and improve the properties of the generated molecules, we incorporate both bond diffusion in the model and additional validity guidance in the sampling phase. Extensive experiments on CrossDocked2020 show that our approach achieves state-of-the-art performance in generating high-affinity molecules while maintaining proper molecular properties and conformational stability, with up to -8.39 Avg. Vina Dock score and 24.5 Success Rate. The code is provided at

Biomolecules,Machine Learning
Rag2Mol: Structure-based drug design based on Retrieval Augmented Generation

Pei-Dong Zhang,Xingang Peng,Rong Han,Ting Chen,Jianzhu Ma

DOI: https://doi.org/10.1101/2024.10.20.619266

2024-10-24

Abstract:Artificial intelligence (AI) has brought tremendous progress to drug discovery, yet identifying hit and lead compounds with optimal physicochemical and pharmacological properties remains a significant challenge. Structure-based drug design (SBDD) has emerged as a promising paradigm, but the inherent data biases and ignorance of synthetic accessibility render SBDD models disconnected from practical drug discovery. In this work, we explore two methodologies, Rag2Mol-G and Rag2Mol-R, both based on retrieval-augmented generation (RAG) to design small molecules to fit a 3D pocket. These two methods involve searching for similar small molecules that are purchasable in the database based on the generated ones, or creating new molecules from those in the database that can fit into a 3D pocket. Experimental results demonstrate that Rag2Mol methods consistently produce drug candidates with superior binding affinities and drug-likeness. We find that Rag2Mol-R provides a broader coverage of the chemical landscapes and more precise targeting capability than advanced virtual screening models. Notably, both workflows identified promising inhibitors for the challenging target PTPN2. Our highly extensible framework can integrate diverse SBDD methods, marking a significant advancement in AI-driven SBDD. The codes are available at: https://github.com/CQ-zhang-2016/Rag2Mol.

Bioinformatics
Geometric Deep Learning for Structure-Based Ligand Design

Alexander S. Powers,Helen H. Yu,Patricia Suriana,Rohan V. Koodli,Tianyu Lu,Joseph M. Paggi,Ron O. Dror

DOI: https://doi.org/10.1021/acscentsci.3c00572

IF: 18.2

2023-11-17

ACS Central Science

Abstract:A pervasive challenge in drug design is determining how to expand a ligand-a small molecule that binds to a target biomolecule-in order to improve various properties of the ligand. Adding single chemical groups, known as fragments, is important for lead optimization tasks, and adding multiple fragments is critical for fragment-based drug design. We have developed a comprehensive framework that uses machine learning and three-dimensional protein-ligand structures to address this challenge. Our method, FRAME, iteratively determines where on a ligand to add fragments, selects fragments to add, and predicts the geometry of the added fragments. On a comprehensive benchmark, FRAME consistently improves predicted affinity and selectivity relative to the initial ligand, while generating molecules with more drug-like chemical properties than docking-based methods currently in widespread use. FRAME learns to accurately describe molecular interactions despite being given no prior information on such interactions. The resulting framework for quality molecular hypothesis generation can be easily incorporated into the workflows of medicinal chemists for diverse tasks, including lead optimization, fragment-based drug discovery, and de novo drug design.

chemistry, multidisciplinary
Fragment-Based Computational Method for Designing GPCR Ligands

Yan Li,Yaping Sun,Yunpeng Song,Dongcheng Dai,Zhixiong Zhao,Qing Zhang,Wenge Zhong,Liaoyuan A Hu,Yingli Ma,Xun Li,Renxiao Wang

DOI: https://doi.org/10.1021/acs.jcim.9b00699

2020-09-28

Abstract:G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors, which is arguably the most important family of drug target. With the technology breakthroughs in X-ray crystallography and cryo-electron microscopy, more than 300 GPCR-ligand complex structures have been publicly reported since 2007, covering about 60 unique GPCRs. Such abundant structural information certainly will facilitate the structure-based drug design by targeting GPCRs. In this study, we have developed a fragment-based computational method for designing novel GPCR ligands. We first extracted the characteristic interaction patterns (CIPs) on the binding interfaces between GPCRs and their ligands. The CIPs were used as queries to search the chemical fragments derived from GPCR ligands, which were required to form similar interaction patterns with GPCR. Then, the selected chemical fragments were assembled into complete molecules by using the AutoT&T2 software. In this work, we chose β-adrenergic receptor (β-AR) and muscarinic acetylcholine receptor (mAChR) as the targets to validate this method. Based on the designs suggested by our method, samples of 63 compounds were purchased and tested in a cell-based functional assay. A total of 15 and 22 compounds were identified as active antagonists for β2-AR and mAChR M1, respectively. Molecular dynamics simulations and binding free energy analysis were performed to explore the key interactions (e.g., hydrogen bonds and π-π interactions) between those active compounds and their target GPCRs. In summary, our work presents a useful approach to the de novo design of GPCR ligands based on the relevant 3D structural information.

Integrable circuit principle for synthesizing voltage-controlled nonlinear impedances

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology

MolHyb: A Web Server for Structure-Based Drug Design by Molecular Hybridization

FragGen: Towards 3D Geometry Reliable Fragment-based Molecular Generation

FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening

LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

ChemGenerator: a web server for generating potential ligands for specific targets

FRAGSITE2: A structure and fragment-based approach for virtual ligand screening

In silico construction of a focused fragment library facilitating exploration of chemical space**

DigFrag as a digital fragmentation method used for artificial intelligence-based drug design

Deep Geometry Handling and Fragment-wise Molecular 3D Graph Generation

SpaceGrow: efficient shape-based virtual screening of billion-sized combinatorial fragment spaces

Autoregressive fragment-based diffusion for pocket-aware ligand design

DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design

Rag2Mol: Structure-based drug design based on Retrieval Augmented Generation

Geometric Deep Learning for Structure-Based Ligand Design

Fragment-Based Computational Method for Designing GPCR Ligands